Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 19/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21178913 | 1.00 | RET (0.58) | RETCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL21179035 | 0.93 | RET (0.49) | RETCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL21179165 | 0.91 | RET (0.58) | RETCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL21179024 | 0.90 | RET (0.53) | RETCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL29897213 | 0.90 | RET (0.53) | RETCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL29897216 | 0.89 | RET (0.60) | RETCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL21178980 | 0.89 | RET (0.60) | RETCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL21179098 | 0.89 | RET (0.63) | RETCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL31639723 | 0.89 | RET (0.46) | RETCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL21179074 | 0.89 | RET (0.46) | RETCYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-111615514-B | Substituted pyrazolo [4,3-C ] pyridine compounds as RET kinase inhibitors | 奥瑞生物药品公司 | 2022-10-11 | — | — | CN | disclosed |